A blood test being developed by Immunomedics Inc. (IMMU) may help in identifying pancreatic cancer at an early-stage better by using clivatuzumab antibody.
Shares in the small biopharmaceutical firm following this announcement were up 9.5 per cent at $4.63.
Immunomedics Chairman and Chief Exeimmucutive Cynthia L. Sullivan noted the early diagnosis of pancreatic cancer has always been a challenge. The company stated that if the disease was detected early then the five-year survival rate could improve by about 20 per cent.
Blood test of a small group with pancreatic cancer surgery found that the test was sensitive by 62 per cent for detecting stage-one pancreatic cancer, in stage two it was 86 per cent and for stages three and four the test was 91 per cent sensitive.
Dr David V. Gold, who developed clivatuzumab, the antibody, said, "Although the number of samples studied is still modest, the test appears to have the ability to detect early disease in a higher percent of patients than any other single test currently available.”
For coming to a conclusion a study involving about 68 patients who had pancreatic cancer surgery and 19 healthy patients were analyzed. Results of the study were presented at the annual Gastrointestinal Cancers Symposium in Orlando, Fla.
SOURCE topnews.us
No comments:
Post a Comment